Allergy最新文献

{"title":"Early Puberty and Risk of Asthma: Meta‐Analysis and Systematic Review","authors":"Fu‐Min Chang, Yung‐Feng Lin, Hsiao‐Chi Chuang, Jhih‐Wei Hsu, Yang‐Ching Chen","doi":"10.1111/all.16471","DOIUrl":"https://doi.org/10.1111/all.16471","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"49 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-Life Diet and Persistent Atopic Dermatitis: A Nationwide Cohort Study.","authors":"Ji Su Lee, Seong Rae Kim, Dong Hyo Kim, Soo Ick Cho, Dong Hun Lee","doi":"10.1111/all.16469","DOIUrl":"https://doi.org/10.1111/all.16469","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study","authors":"Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan","doi":"10.1111/all.16446","DOIUrl":"https://doi.org/10.1111/all.16446","url":null,"abstract":"BackgroundThis study compared the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria.MethodsThis double‐blind, randomized, active‐controlled Phase 3 study (NCT04426890) included two 12‐week treatment periods (TPs). In TP1, patients received CT‐P39 300 mg, ref‐OMA 300 mg, CT‐P39 150 mg, or ref‐OMA 150 mg. In TP2, patients treated with ref‐OMA 300 mg were rerandomized to CT‐P39 300 mg or ref‐OMA 300 mg; patients initially randomized to CT‐P39 300 mg continued this regimen; and patients initially randomized to CT‐P39 or ref‐OMA 150 mg received 300 mg dosing with the same drug. The primary endpoint for the assessment of therapeutic equivalence of CT‐P39 300 mg and ref‐OMA 300 mg was change from baseline in weekly itch severity score (ISS7) at week 12.ResultsIn TP1, 619 patients were randomized (CT‐P39 300 mg, <jats:italic>n</jats:italic> = 204; ref‐OMA 300 mg, <jats:italic>n</jats:italic> = 205; CT‐P39 150 mg, <jats:italic>n</jats:italic> = 107; ref‐OMA 150 mg, <jats:italic>n</jats:italic> = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12; confidence intervals (CIs) were within predefined equivalence margins: global analysis: treatment difference 0.77, 95% CI –0.37 to 1.90; US analysis: treatment difference 0.70, 90% CI –0.22 to 1.63. The proportion of patients experiencing ≥ 1 treatment‐related adverse event was comparable across groups. Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.ConclusionsEquivalent efficacy was observed between CT‐P39 and ref‐OMA, with comparable safety also evident.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"127 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbid Bronchial Asthma, Atopic Dermatitis and Hashimoto's Thyroiditis Are Risk Factors for Early‐Onset, Severe and Prolonged Alopecia Areata","authors":"Annika Friedrich, Marie‐Therese Schmitz, Yasmina Gossmann, Silke Redler, Bettina Blaumeiser, Gerhard Lutz, Ulrike Blume‐Peytavi, Markus M. Nöthen, Regina C. Betz, F. Buket Basmanav","doi":"10.1111/all.16468","DOIUrl":"https://doi.org/10.1111/all.16468","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"36 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Algorithms in Allergy: Organ‐Specific Allergen Challenges for the Phenotyping of Chronic Respiratory Diseases","authors":"Dulce Sanchez‐Torralvo, Almudena Testera‐Montes, Guillermo Bentabol‐Ramos, Ibon Eguiluz‐Gracia, Ralph Mösges, Maria J. Torres","doi":"10.1111/all.16470","DOIUrl":"https://doi.org/10.1111/all.16470","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis","authors":"Jonathan Bar, Ester Del Duca, Eden David, Swaroop Bose, Gabriella Chefitz, Patrick M. Brunner, Robert Bissonnette, Emma Guttman‐Yassky","doi":"10.1111/all.16466","DOIUrl":"https://doi.org/10.1111/all.16466","url":null,"abstract":"IntroductionChronic hand eczema (CHE) is a highly prevalent inflammatory skin condition which is often resistant to conventional treatments. Molecular insights of CHE remain limited. Tape stripping combined with high‐throughput RNA sequencing can now provide a better insight into CHE pathogenesis in a minimally invasive fashion.MethodsWe collected tape strip samples from lesional and non‐lesional skin of 66 patients with moderate‐to‐severe CHE, comprising 33 with and 33 without comorbid atopic dermatitis (AD), and performed bulk RNA sequencing. Results were compared to tape strips from palmar skin of age/race/sex‐matched healthy controls (HC). Differentially expressed genes (DEGs) (fold change/FCH &gt; 1.5 and false discovery rate/FDR &lt; 0.05) were calculated and correlated with clinical severity scores including hand eczema severity index (HECSI) and modified total lesion symptoms score (mTLSS).ResultsTape strip isolates detected a common phenotype in CHE lesions regardless of AD status, including upregulated type‐1 (<jats:italic>IL12RB2</jats:italic>, <jats:italic>IFNGR1</jats:italic>, <jats:italic>IFNGR2</jats:italic>, <jats:italic>MX1</jats:italic>) and type‐2‐associated inflammatory mediators (<jats:italic>CCL22</jats:italic>, <jats:italic>CCL24</jats:italic>, OX40/<jats:italic>TNFRSF4</jats:italic>, TSLPR/<jats:italic>CRLF2</jats:italic>, <jats:italic>GATA3</jats:italic>), paralleled by downregulated epidermal barrier markers (i.e., <jats:italic>FLG</jats:italic> or <jats:italic>LORICRIN</jats:italic>). Non‐lesional skin demonstrated a similar, albeit milder, dysregulation pattern, with additional reduction in type‐17 pathways. Lesional skin of CHE patients without AD showed greater skewing towards type‐1 immunity (<jats:italic>IL15RA</jats:italic>, <jats:italic>CXCL9</jats:italic>), while CHE from AD patients showed a more pronounced type‐2 inflammatory pattern (<jats:italic>IL13</jats:italic>, <jats:italic>CCL17</jats:italic>) and their gene expression biomarkers had greater and more significant correlations with clinical severity markers.ConclusionTape stripping can capture detailed immune and skin barrier abnormalities in CHE and identify potential novel subtype‐specific treatment targets. Stronger correlations in patients with AD suggest a more homogenous disease phenotype than in CHE non‐AD patients.Trial Registration: NCT03728504","PeriodicalId":122,"journal":{"name":"Allergy","volume":"12 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Impact of COVID-19 on Subcutaneous Immunotherapy Persistence and Efficacy in Allergic Rhinitis.","authors":"Xuan Yuan, Liyuan Liu, Benjian Zhang, Shaobing Xie, Lai Meng, Wei Zhong, Jiaxin Jia, Hua Zhang, Weihong Jiang, Zhihai Xie","doi":"10.1111/all.16467","DOIUrl":"https://doi.org/10.1111/all.16467","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort.","authors":"Guillaume Lefèvre, Séverine Bleuse, Mathieu Puyade, Guillaume Moulis, Antoine Néel, Noémie Abisror, Antoine Baudet, Bernard Bonnotte, Jérémie Dion, Antoine Dossier, Maximilien Grall, François Lifermann, Nicolas Limal, Bertrand Lioger, Irène Machelart, Catherine Mohr, Roderau Outh, Viviane Queyrel-Moranne, Borhane Slama, Ludovic Tréfond, Wadih Abou Chahla, Félix Ackerman, Nabil Belfeki, Alice Berezne, Jean-Sébastien Blade, Mohammed Azzedine Bouderbala, Safia Chebrek, Vincent Cottin, Sébastien De Almeida, Adèle De Masson, Frédéric Dezoteux, Tiphaine Goulenok, Vincent Jachiet, Mathieu Jouvray, Irina Latu, Emmanuel Ledoult, Amélie Leurs, Maxime Lugosi, Michael Martin, Sara Melboucy-Belkhir, Chafika Morati-Hafsaoui, Thomas Quemeneur, Julien Rohmer, Frédérique Roy-Peaud, Sébastien Sanges, Nicolas Schleinitz, Delphine Staumont-Salle, Camille Taillé, Louis Terriou, Nathalie Tieulie, Japhete Darline Elenga Koenga, Laurent Schwarb, Kewin Panel, Jean-Emmanuel Kahn, Matthieu Groh","doi":"10.1111/all.16463","DOIUrl":"https://doi.org/10.1111/all.16463","url":null,"abstract":"<p><strong>Background: </strong>Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample-size and/or follow-up duration are available.</p><p><strong>Methods: </strong>The COHESion study is a national prospective multicenter multidisciplinary cohort recruiting both adults or children with the spectrum of eosinophilic disorders (including reactive HE/HES [HE/HES-R], idiopathic HES [HES-I], lymphocytic HES [HES-L], neoplastic HE/HES [HE/HES-N], HE of unknown significance [HE-US], as well as IgG4-related disease [IgG4RD] or ANCA-negative eosinophilic granulomatosis with polyangiitis [EGPA] overlaps). Patients are followed-up yearly. All data about final diagnosis, organ involvement assessments, and outcome profiles in HES-I were captured and analyzed centrally by HES expert centers.</p><p><strong>Results: </strong>From May 2019 to November 2023, 779 patients were included. For this preliminary analysis, 550 cases were available for centralized review (mean ± SD age: 56 ± 18 years, 42% of female patients). The final diagnoses were HES-I (47%), HE/HES-R (16%), HE-US (15%), HE/HES-N (7%), HE/HES-L (6%), IgG4RD (2%), and ANCA-negative EGPA (7%). In the 258 HES-I patients, outcome profiles were classified as follows: 16.3% had a \"single-flare\" without further relapse, 28.3% had a \"relapsing-remitting\" disease when there was at least a 6-month period free of symptoms between two flares, 46.1% had a \"persistent disease\" requiring continuous treatment to avoid relapses (9.3% remained unclassified because of insufficient follow-up).</p><p><strong>Conclusions: </strong>The COHESion cohort is the first nationwide prospective multicenter study collecting data on the full spectrum of HE/HES disorders. This preliminary analysis confirms that idiopathic HES patients have various outcome profiles, suggesting different underlying pathophysiological mechanisms and the need of patient-specific management.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04018118.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of WNT5a and TGF-β1 in Airway Remodelling and Severe Asthma.","authors":"Tariq Daud, Sheree Roberts, Nazanin Zounemat Kermani, Matthew Richardson, Liam G Heaney, Ian M Adcock, Yassine Amrani, Peter Bradding, Salman Siddiqui","doi":"10.1111/all.16445","DOIUrl":"https://doi.org/10.1111/all.16445","url":null,"abstract":"<p><strong>Background: </strong>Airway remodelling is a feature of severe asthma with airway epithelial damage observed frequently. We evaluated the role of WNT5a and TGF-β₁ in asthmatic airway biopsies and in sputum and bronchial brushings assessed their role in remodelling.</p><p><strong>Methods: </strong>WNT5a and TGF-β₁ protein expression were assessed in the lamina propria epithelium of people with asthma (GINA 1-3, n-8 and GINA 4-5, n-14) and healthy subjects (n-9), alongside relevant remodelling markers. The effects of WNT5a and TGF-β₁ on BEAS-2B epithelial cell wound healing and differentiation were assessed in vitro. Replication was performed in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) study in sputum (n = 120) and bronchial brushes (n = 147).</p><p><strong>Results: </strong>WNT5a and TGF-β₁ protein expression were significantly increased in the airway epithelium and lamina propria in asthma patients with concurrent airflow limitation or severe disease. Furthermore, WNT5a protein expression in the lamina propria correlated with tissue eosinophils and vascular remodelling. Airway epithelial WNT5a was co-localised predominantly to airway basal cells and correlated with Th17 gene expression (r = 0.40, p = 0.025) and both the % intact (r_s = 0.54, p = 0.001) and % denuded epithelium (r_s = -0.39, p = 0.003). Experiments in BEAS-2B cells confirmed that WNT5a at maximal physiological concentrations (1 μg/mL), promoted epithelial wound healing, independently of TGF-β₁, as well as induction of EMT-like morphology. WNT5a mRNA was associated with severe asthma, airflow limitation, sputum eosinophilia and Th2, and Th17 and neutrophil activation transcriptomes in sputum in U-BIOPRED.</p><p><strong>Conclusion: </strong>WNT5a is associated with both airway remodelling and severe asthma.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT01982162.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.","authors":"Bernardo Sousa-Pinto, Rafael José Vieira, Antonio Bognanni, Sara Gil-Mata, Renato Ferreira-da-Silva, André Ferreira, António Cardoso-Fernandes, Henrique Ferreira-Cardoso, Manuel Marques-Cruz, Vítor Henrique Duarte, João Castro-Teles, Miguel Campos-Lopes, Ana Teixeira-Ferreira, Nuno Lourenço-Silva, Ivan Chérrez-Ojeda, Anna Bedbrook, Ludger Klimek, Juan Jose Yepes Nuñez, Torsten Zuberbier, João A Fonseca, Holger J Schünemann, Jean Bousquet","doi":"10.1111/all.16384","DOIUrl":"10.1111/all.16384","url":null,"abstract":"<p><strong>Background: </strong>Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network-meta-analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR.</p><p><strong>Methods: </strong>We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence was assessed using GRADE-NMA.</p><p><strong>Results: </strong>We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ranked interventions for efficacy outcomes, being regularly associated with clinically meaningful larger improvements when compared to other active treatments. Considering drug classes, INAH+INCS were the highest-ranked interventions for all outcomes in which they were assessed, followed in most cases by INCS. In 105 out of 184 comparisons in seasonal AR, and 28 out of 97 comparisons in perennial AR, certainty of evidence was considered \"high\" or \"moderate\".</p><p><strong>Conclusion: </strong>Intranasal medications for AR display clinically relevant differences in their efficacy, but all show a good safety profile. To our knowledge, this is the first network meta-analysis comparing INAH, INCS, and INAH+INCS in AR, providing relevant evidence for guideline developers and practising physicians on the most efficacious treatments.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":"94-105"},"PeriodicalIF":12.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}